Compare Johnson & Johnson (JNJ) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Procter & Gamble Co — how do they compare? Johnson & Johnson trades at $259.78 (market cap $630.94B), while Procter & Gamble Co trades at $145.1 (market cap $340.39B). The key difference: Johnson & Johnson is the larger of the two by market cap, and Procter & Gamble Co pays the higher dividend (2.97%). Which is the better fit depends on your goals.
| JNJ | PG | |
|---|---|---|
Market Cap | $630.94B | $340.39B |
Volume | 6,156,228 | 6,423,436 |
Sector | Health | Consumer Staples |
52-Week High | $267.24 | $167.18 |
52-Week Low | $172.78 | $138.10 |
Enterprise Value | $659.21B | $366.23B |
Dividend Yield | 2.05% | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.24, up 0.88% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $282.33. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The company maintains strong profitability, including a 67.91% gross margin and 21.48% net income margin, supported by consistent dividend payments, including a recent $1.34 per share payout.
JNJ offers stability with a 64-year dividend growth streak and robust fundamentals, but risks include rising debt-to-asset ratios (24.06% in 2025) and sector volatility. Upside potential hinges on execution of growth initiatives and healthcare market dynamics, with analysts favoring a buy rating (52.5% consensus).
Procter & Gamble (PG) trades at $144.84, down 0.64% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.90. Fundamentals show robust profitability, including an 18.44% net income margin and 30.13% ROE, though valuation ratios like P/E of 22.12 and P/S of 4.08 are at premiums. Recent news highlights a WNBA partnership and a rejected mini-tender offer, while cash flow trends indicate stable operations.
PG offers a stable outlook with consistent dividend growth and efficient supply chain improvements, but faces risks from premium valuations and soft demand concerns. Analyst consensus is bullish with a $161.20 price target, though near-term upside may be limited by economic headwinds. Investment appeal lies in its defensive qualities and dividend reliability, balanced against competitive and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
